Stay updated on Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Naples, Italy, 80131 was added as a study location, replacing Napoli, Italy, 80131. The page revision was updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-25T07:09:46.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    Added updates to eligibility criteria, including prior PD-1/PD-L1/CTLA-4 exposure and prior MSD pembrolizumab participation. Expanded and clarified endpoint definitions (EFS, pathCR, OS) and adverse events across neoadjuvant/adjuvant cohorts, and updated study identifiers and revision metadata (EudraCT number, v3.4.3) with dates.
    Difference
    0.4%
    Check dated 2026-03-10T17:33:18.000Z thumbnail image
  4. Check
    23 days ago
    No Change Detected
  5. Check
    38 days ago
    Change Detected
    Summary
    Gastric cancer is now listed as the study focus. The Resources section now includes the Genetic and Rare Diseases Information Center, and the page revision has been updated to v3.4.2.
    Difference
    0.1%
    Check dated 2026-02-17T03:08:54.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-09T22:52:36.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    A notice about government funding delays is now displayed, stating the site information may not be up to date and directing users to cc.nih.gov and opm.gov for status updates.
    Difference
    0.1%
    Check dated 2026-02-02T20:59:34.000Z thumbnail image
  8. Check
    59 days ago
    Change Detected
    Summary
    The changes are UI/metadata related and do not alter core study content, endpoints, or eligibility. New items include a glossary display toggle, and revision/version metadata (Revision: v3.4.0), while older QC labels (Last Update Submitted that met QC Criteria) and No FEAR Act data were removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-26T21:29:14.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial page.